The detection of various gene mutations, such as those in Ras and Raf, are important for risk stratification and identifying appropriate treatment plans for multiple myeloma (MM) patients. This genetic analysis has traditionally been performed through the extraction of bone marrow, which is an invasive and often painful procedure. In this interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Suzanne Trudel, MD, MSc, FRCPC, of the Princess Margaret Hospital, Toronto, Canada, discusses how her group has developed a liquid biopsy to detect these mutations with high sensitivity and specificity.
Detecting common mutations in MM patients through liquid biopsy
